Vident Advisory LLC Grows Position in Boston Scientific Co. (NYSE:BSX)

Vident Advisory LLC lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,905 shares of the medical equipment provider's stock after buying an additional 8,292 shares during the period. Vident Advisory LLC's holdings in Boston Scientific were worth $9,102,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Mechanics Bank Trust Department purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $415,000. Highland Capital Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $4,887,000. Covenant Asset Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $3,405,000. Beacon Investment Advisory Services Inc. boosted its position in shares of Boston Scientific by 31.7% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock valued at $1,744,000 after buying an additional 4,702 shares during the last quarter. Finally, Oak Harvest Investment Services boosted its position in shares of Boston Scientific by 262.5% during the fourth quarter. Oak Harvest Investment Services now owns 40,776 shares of the medical equipment provider's stock valued at $3,642,000 after buying an additional 29,526 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.5%

Shares of BSX opened at $106.61 on Tuesday. The business's 50 day moving average is $99.39 and its 200 day moving average is $96.90. The company has a market capitalization of $157.72 billion, a PE ratio of 85.29, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 12-month low of $71.88 and a 12-month high of $107.36. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the company earned $0.56 EPS. Research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 263,163 shares of company stock valued at $27,129,540. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BSX. Robert W. Baird raised their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Citigroup raised their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Barclays raised their target price on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. BTIG Research reissued a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Raymond James raised their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Twenty-three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and a consensus target price of $114.74.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.